Temporary dependency of steroid-receptor prognostic value in breast cancer

被引:1
作者
Cañizares, F
De las Heras, M
Pérez, M
Tovar, I
Sola, J
Viñals, I
Salinas, J
Martínez, P
机构
[1] Hosp Univ Virgen de la Arrixaca, Serv Anal Clin, Murcia 30120, Spain
[2] Hosp Univ Virgen de la Arrixaca, Serv Oncol Radioterap, Murcia 30120, Spain
[3] Hosp Univ Virgen de la Arrixaca, Serv Anat Pathol, Murcia 30120, Spain
来源
MEDICINA CLINICA | 2001年 / 117卷 / 20期
关键词
steroid receptors; prognostic factor; breast cancer;
D O I
10.1016/S0025-7753(01)72251-8
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: The influence of prognostic factors in breast cancer may change during follow-up. Our aim was therefore to look for time-related changes in hazard ratios for steroid receptor status and the risk of relapse. PATIENTS AND METHOD: We studied 455 patients with operable primary breast cancer during a mean follow-up period of 72 months (range, 42-130 months). Clinical and histological characteristics were assessed and estrogen receptor (ER) and progesterone receptor (PgR) status were determined and compared to disease-free survival (DFS) and overall survival (OS). Analysis of DFS included fitting a multivariate Cox proportional hazards model, testing for non-proportionality, and examining diagnostic plots. RESULTS: A total of 66.8% of the tumors were ER positive and 54.7% PgR positive. Receptor status is highly associated with menopausal status, histological grade, peritumoral lymphatic or blood vessel invasion and mitotic index. No correlation was found between steroid receptor status and tumor size, node status or tumor stage. In univariate analysis, ER-/PR- vs ER+/PR+ display a hazard ratio of 2.15 (IC del 95%, 1.59-2.99) for DFS (p = 0.001) and 1.95 (IC del 95%, 1.38-2.59) for OS (p = 0.0043). In multivariate analysis, steroid receptor status, node status and mitotic index were independent prognostic factors for DFS and OS. By using Cox regression time-dependent covariates model, we show that the steroid receptor status hazard ratio is 5.6 at diagnosis, decreases after 4 years, and loses its significance after 10 years of follow-up. CONCLUSION: In patients with breast cancer the status steroid receptor have a relatively limited prognostic value and is lost within the first years.
引用
收藏
页码:761 / 765
页数:5
相关论文
共 39 条
[1]   Neoadjuvant therapy in breast cancer: Can we define its role? [J].
Aapro, MS .
ONCOLOGIST, 2001, 6 :36-39
[2]  
ALLEGRA JC, 1980, CANCER, V45, P792, DOI 10.1002/1097-0142(19800215)45:4<792::AID-CNCR2820450430>3.0.CO
[3]  
2-X
[4]  
BERGER U, 1991, CANCER RES, V51, P239
[5]   HISTOLOGICAL GRADING AND PROGNOSIS IN BREAST CANCER - A STUDY OF 1409 CASES OF WHICH 359 HAVE BEEN FOLLOWED FOR 15 YEARS [J].
BLOOM, HJG ;
RICHARDSON, WW .
BRITISH JOURNAL OF CANCER, 1957, 11 (03) :359-&
[6]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[7]   PREDICTION OF RELAPSE OR SURVIVAL IN PATIENTS WITH NODE-NEGATIVE BREAST-CANCER BY DNA FLOW-CYTOMETRY [J].
CLARK, GM ;
DRESSLER, LG ;
OWENS, MA ;
POUNDS, G ;
OLDAKER, T ;
MCGUIRE, WL .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (10) :627-633
[8]  
Clarke M, 1998, LANCET, V351, P1451
[9]  
COX DR, 1972, J R STAT SOC B, V34, P187
[10]   RELATIVE WORTH OF ESTROGEN OR PROGESTERONE-RECEPTOR AND PATHOLOGIC CHARACTERISTICS OF DIFFERENTIATION AS INDICATORS OF PROGNOSIS IN NODE NEGATIVE BREAST-CANCER PATIENTS - FINDINGS FROM NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT PROTOCOL B-06 [J].
FISHER, B ;
REDMOND, C ;
FISHER, ER ;
CAPLAN, R .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (07) :1076-1087